Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Judge rules against...

    Judge rules against Pharma Bro on investor losses

    Written by Ruby Khatun Khatun Published On 2018-02-28T09:30:59+05:30  |  Updated On 28 Feb 2018 9:30 AM IST
    Judge rules against Pharma Bro on investor losses

    NEW YORK: "Pharma Bro" Martin Shkreli was responsible for nearly $10.5 million in losses in a securities fraud scheme, a judge ruled Monday, a blow to the defense that could result in a harsher sentence for the eccentric former pharmaceutical company CEO.


    U.S. District Judge Kiyo Matsumoto rejected arguments by Shkreli's lawyers that investors in two failed hedge funds didn't suffer actual losses because he compensated them with drug company stock that, in the end, more than covered their initial investments.


    In a written decision in federal court in Brooklyn, the judge found Shkreli should be penalized for the losses because he made risky transactions with investors' millions without their permission.


    After dipping into investor money from one of the hedge funds to keep his drug company startup afloat, Shkreli "used some the funds to satisfy both personal and unrelated professional obligations," including a $900,000 debt for a bad stock market trade, she wrote.


    Shkreli was convicted at trial last year, remains in jail and faces up to 20 years in prison at his sentencing on March 9.


    The defense had hoped that under sentencing guidelines he would get little or even no prison time. Monday's decision on losses appears certain to work against him.


    One of Shkreli's attorneys, Ben Brafman, said in a statement that he was "disappointed by the ruling but still hopeful that the court will find it in her heart to impose a reasonably lenient sentence."


    At a hearing last week, prosecutors asked the judge to order Shkreli to forfeit about $7.3 million in assets, including a one-of-a-kind Wu-Tang Clan "Once Upon a Time in Shaolin" album that he has boasted he bought for $2 million, as part of the punishment. The judge hasn't ruled on that request.


    Shkreli, 34, is perhaps best known for boosting the price of a life-saving drug by 5,000 percent and for trolling his critics on social media, where he became known as "Pharma Bro." His bail was revoked last year after he posted a veiled threat against Hillary Clinton.

    federal courtInvestorjudgeJudge Kiyo MatsumotoMartin ShkreliPharma Bropharmaceutical companysecurities fraud scheme
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok